What Is 7-OH and Why Kratom Regulators Care

7-OH is shorthand for 7-hydroxymitragynine, one of the two primary alkaloids in the kratom plant. It is far more potent than mitragynine, the other major alkaloid, and acts as a full opioid receptor agonist. In concentrated form, 7-OH produces effects comparable to prescription opioids. The FDA issued a formal warning in 2024 stating that products containing 7-OH can cause serious harm, including respiratory depression, seizures, and death. Smoke shops, gas stations, and online vendors sell 7-OH products as semi-legal alternatives to regulated opioids. Here is what you need to know.

What Makes 7-OH Different From Regular Kratom

7-hydroxymitragynine is 13 times more potent than morphine at opioid receptors.
Regular kratom leaf contains only small amounts (about 2% of total alkaloid content). Concentrated 7-OH products isolate and amplify this compound.
The FDA warned that 7-OH products can cause respiratory depression, the same mechanism that kills in opioid overdoses.
7-OH products are sold as shots, gummies, tablets, and powders in convenience stores and online.
Unlike kratom leaf, concentrated 7-OH carries overdose risk comparable to pharmaceutical opioids.

How 7-OH Acts on the Brain

Mitragynine, the dominant alkaloid in kratom leaf, is a partial opioid agonist. It activates mu-opioid receptors weakly. 7-hydroxymitragynine is a full agonist with high binding affinity. In pharmacological terms, this means 7-OH produces stronger pain relief, greater sedation, more euphoria, and significantly more respiratory depression than whole-leaf kratom.

The concentration matters. When someone chews kratom leaf or drinks kratom tea, they ingest mostly mitragynine with trace 7-OH. When someone takes a concentrated 7-OH extract, they receive a pharmacologically different product that behaves like a potent opioid.

The FDA Warning

In 2024, the FDA released a consumer update titled “Products Containing 7-OH Can Cause Serious Harm.” The warning cited reports of adverse events including seizures, respiratory depression, liver injury, and at least one death linked to concentrated 7-OH products. The agency emphasized that these products are marketed without safety data, dosing guidelines, or quality controls.

The FDA stated: “Products containing 7-hydroxymitragynine have been associated with serious adverse events, including death. Consumers should avoid these products.” The warning applies specifically to concentrated 7-OH extracts, not to whole-leaf kratom, though the FDA maintains concerns about kratom in general.

How 7-OH Products Are Sold

7-OH products have expanded rapidly in the unregulated supplement market. They are sold under various brand names in formats designed to look like energy supplements or wellness shots. Common product types include:

Liquid shots: Small bottles containing concentrated 7-OH extract, often sold at gas station counters.
Gummies and tablets: Dosed to deliver specific milligram amounts of isolated 7-OH.
Powders: Bulk 7-OH powder marketed for “research” or sold as enhanced kratom.

Marketing for these products frequently downplays the opioid-like pharmacology. Labels may not accurately disclose 7-OH content. Independent testing has found significant variation between labeled and actual alkaloid concentrations.

Dependence and Withdrawal Risk

Because 7-OH is a potent opioid agonist, regular use creates physical dependence. Withdrawal from concentrated 7-OH products mirrors opioid withdrawal: muscle aches, anxiety, insomnia, nausea, diarrhea, and intense cravings. Users who started with kratom tea and transitioned to 7-OH extracts often report that the withdrawal from 7-OH is substantially worse than from whole-leaf kratom.

The escalation pattern is predictable. Tolerance to 7-OH develops quickly. Users increase their dose frequency and dose size. This mirrors the classic progression of opioid use disorder.

Where Regulation Stands

As of early 2026, 7-OH is not a federally scheduled substance. Some states have moved to restrict or ban it. The FDA’s authority to regulate 7-OH products is limited because they are marketed as dietary supplements rather than drugs. The DEA has considered scheduling kratom alkaloids but has not finalized action.

The regulatory gap means consumers are responsible for their own safety with a product that the FDA says can kill. If you or someone you know is using 7-OH products regularly, the risk profile is not meaningfully different from using illicit opioids. Treatment resources are available.